Several years ago, Al Mann founded MannKind (MNKD) with a vision. Part of that vision was Afrezza. Early investors eagerly supported the concept of his vision. It was easy to buy into. Inhaled insulin vs. needles… "Where do I sign up". Unfortunately, the MannKind story has been a challenged one, and investors (particularly the early investors) have had more heartache than not. Early enthusiasm has given way to escalating frustration.
Over the years, what we have seen is a young company struggling along trying to swim upstream in a river where the strength